SRGA.Q Stoklara Genel Bakış Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. Daha fazla detay
Risk Analizi + 2 daha fazla risk
Tüm Risk Kontrollerini Gör {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Surgalign Holdings, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Surgalign Holdings Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$0.018 52 Haftanın En Yüksek Seviyesi US$4.00 52 Haftanın En Düşük Seviyesi US$0.005 Beta 1.49 1 Aylık Değişim 63.64% 3 Aylık Değişim -80.00% 1 Yıllık Değişim -99.50% 3 Yıllık Değişim -99.97% 5 Yıllık Değişim -99.99% Halka arzdan bu yana değişim -100.00%
Son Haberler & Güncellemeler
Surgalign Holdings, Inc. Files Form 15 Nov 14
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index Jun 23 Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Surgalign Holdings, Inc. Filed for Bankruptcy Jun 20
Daha fazla güncelleme görün
Surgalign Holdings, Inc. Files Form 15 Nov 14
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index Jun 23 Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Surgalign Holdings, Inc. Filed for Bankruptcy Jun 20
Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares Jun 12
Price target decreased by 19% to US$2.22 May 18
Consensus estimates of losses per share improve by 87% May 18
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research May 09
Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Consensus revenue estimates fall by 38% Apr 06
Full year 2022 earnings: EPS misses analyst expectations Apr 01
Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System Dec 16 Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million. Nov 17
Price target decreased to US$5.00 Nov 17
Consensus EPS estimates fall by 14% Nov 09
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 04
Price target decreased to US$11.00 Nov 03
Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022 Nov 03
Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 26
Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures Sep 27
Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System Sep 16
Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform Aug 25
Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system Aug 24 Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022
Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue Aug 09
Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary Aug 05
Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission Aug 04
Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 02
Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio Jul 07
Chief Financial Officer recently bought US$100k worth of stock May 20
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 12
Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022 May 12
Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System May 06
Price target decreased to US$1.00 Apr 27
Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022 Apr 12
Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022 Apr 08
Consensus forecasts updated Mar 22
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 18 Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer Mar 10
Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System Jan 19
Surgalign Holdings - A Future Of Digital Surgery Dec 21
Price target decreased to US$2.85 Nov 25
Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020) Nov 12
Sizing Up Surgalign Sep 23
Independent Director Jeffrey Lightcap has left the company Sep 17
Chairman Stuart Simpson has left the company Sep 17
Surgalign Holdings: Insiders Are Buying Aug 28
Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation Aug 20
President recently bought US$1.0m worth of stock Aug 14
Surgalign Holdings: Pinocchio Has A Happy Ending Aug 10
Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020) Aug 08
Price target decreased to US$4.21 Aug 07
Surgalign Holdings: A Marketing Ploy Jun 29 Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index
Surgalign reports inducement grants under Nasdaq listing rule Jun 04
First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020) May 11
Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System May 11
Surgalign Holdings, Inc. (NasdaqGS:SRGA) acquired Medical Device Prototyping and Manufacturing Facility in San Diego. May 08
Independent Director has left the company May 08
VP, Chief Accounting Officer & Corporate Controller has left the company May 08
Full year 2020 earnings released: US$2.61 loss per share (vs US$2.91 loss in FY 2019) Mar 18 Surgalign Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020
Shirley Weis Not to Stand for Re-Election as Director of Surgalign Holdings, Inc. At 2021 Annual Meeting of Stockholders Mar 14
Have Insiders Been Buying Surgalign Holdings, Inc. (NASDAQ:SRGA) Shares? Mar 08
Price target lowered to US$5.00 Mar 08
Surgalign Holdings, Inc. to Report Q4, 2020 Results on Mar 11, 2021 Feb 26
Surgalign Holdings, Inc., Annual General Meeting, May 04, 2021 Feb 13
Surgalign Holdings Announces the Commercial Launch of ViBone® Moldable and the First Clinical Implantation Jan 13
Surgalign Holdings : Strong Upside Potential Jan 11
Surgalign Holdings, Inc. Appoints Pawel (Paul) Lewicki to Board of Directors Nov 24
Surgalign Holdings, Inc. and Aziyo Biologics, Inc. Announce Expanded Distribution Agreement Nov 18 Hissedar Getirileri SRGA.Q US Medical Equipment US Pazar 7D 16.1% -0.2% 0.2% 1Y -99.5% 14.4% 23.1%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: SRGA.Q geçen yıl % 14.4 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: SRGA.Q geçen yıl % 23.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is SRGA.Q's price volatile compared to industry and market? SRGA.Q volatility SRGA.Q Average Weekly Movement 40.5% Medical Equipment Industry Average Movement 8.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
İstikrarlı Hisse Senedi Fiyatı: SRGA.Q hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: SRGA.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 28% dan 40% a yükseldi.
Şirket Hakkında Daha fazla göster Surgalign Holdings, Inc. Temel Bilgiler Özeti Surgalign Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? SRGA.Q temel i̇stati̇sti̇kler Piyasa değeri US$165.30k Kazançlar(TTM ) -US$50.49m Gelir(TTM ) US$78.12m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) SRGA.Q gelir tablosu (TTM ) Gelir US$78.12m Gelir Maliyeti US$26.03m Brüt Kâr US$52.09m Diğer Giderler US$102.58m Kazançlar -US$50.49m
Son Raporlanan Kazançlar
Mar 31, 2023
Hisse başına kazanç (EPS) -5.50 Brüt Marj 66.68% Net Kâr Marjı -64.63% Borç/Özkaynak Oranı -54.1%
SRGA.Q uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2023/10/04 00:57 Gün Sonu Hisse Fiyatı 2023/10/02 00:00 Kazançlar 2023/03/31 Yıllık Kazançlar 2022/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Surgalign Holdings, Inc. 14 Bu analistlerden , raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Raymond Myers Benchmark Company Michael Gorman BTIG William Plovanic Canaccord Genuity
Göster 11 daha fazla analist 
